Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study

Shai Levi; Yotam Bronstein; Neta Goldschmidt; Fortunato Morabito; Tomer Ziv-Baran; Giovanni Del Poeta; Osnat Bairey; Maria Ilaria Del Principe; Riva Fineman; Francesca Romana Mauro; Odit Gutwein; Gianluigi Reda; Rosa Ruchlemer; Paolo Sportoletti; Luca Laurenti; Lev Shvidel; Marta Coscia; Tamar Tadmor; Marzia Varettoni; Ariel Aviv; Roberta Murru; Andrei Braester; Annalisa Chiarenza; Andrea Visentin; Daniela Pietrasanta; Giacomo Loseto; Antonella Zucchetto; Riccardo Bomben; Jacopo Olivieri; Antonio Neri; Davide Rossi; Gianluca Gaidano; Livio Trentin; Robin Foà; Antonio Cuneo; Chava Perry; Valter Gattei; Massimo Gentile; Yair Herishanu

doi:10.1002/ajh.26779

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study

Shai Levi
, Yotam Bronstein
, Neta Goldschmidt
, Fortunato Morabito
, Tomer Ziv-Baran
, Giovanni Del Poeta
, Osnat Bairey
, Maria Ilaria Del Principe
, Riva Fineman
, Francesca Romana Mauro
, Odit Gutwein
, Gianluigi Reda
, Rosa Ruchlemer
, Paolo Sportoletti
, Luca Laurenti
, Lev Shvidel
, Marta Coscia
, Tamar Tadmor
, Marzia Varettoni
, Ariel Aviv

Roberta Murru, Andrei Braester, Annalisa Chiarenza, Andrea Visentin, Daniela Pietrasanta, Giacomo Loseto, Antonella Zucchetto, Riccardo Bomben, Jacopo Olivieri, Antonio Neri, Davide Rossi, Gianluca Gaidano, Livio Trentin, Robin Foà, Antonio Cuneo, Chava Perry, Valter Gattei, Massimo Gentile, Yair Herishanu

Tel Aviv University

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E24-E27
Journal	American Journal of Hematology
Volume	98
Issue number	2
DOIs	https://doi.org/10.1002/ajh.26779
State	Published - Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antineoplastic Combined Chemotherapy Protocols/adverse effects
Cyclophosphamide/therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
Rituximab/therapeutic use
Vidarabine/therapeutic use

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26779

Cite this

Levi, S., Bronstein, Y., Goldschmidt, N., Morabito, F., Ziv-Baran, T., Del Poeta, G., Bairey, O., Del Principe, M. I., Fineman, R., Mauro, F. R., Gutwein, O., Reda, G., Ruchlemer, R., Sportoletti, P., Laurenti, L., Shvidel, L., Coscia, M., Tadmor, T., Varettoni, M., ... Herishanu, Y. (2023). Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study. American Journal of Hematology, 98(2), E24-E27. https://doi.org/10.1002/ajh.26779

@article{4dd2b07028f04ae39010b561c3dcf7f7,

title = "Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study",

keywords = "Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cyclophosphamide/therapeutic use, Humans, Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy, Rituximab/therapeutic use, Vidarabine/therapeutic use",

author = "Shai Levi and Yotam Bronstein and Neta Goldschmidt and Fortunato Morabito and Tomer Ziv-Baran and \{Del Poeta\}, Giovanni and Osnat Bairey and \{Del Principe\}, \{Maria Ilaria\} and Riva Fineman and Mauro, \{Francesca Romana\} and Odit Gutwein and Gianluigi Reda and Rosa Ruchlemer and Paolo Sportoletti and Luca Laurenti and Lev Shvidel and Marta Coscia and Tamar Tadmor and Marzia Varettoni and Ariel Aviv and Roberta Murru and Andrei Braester and Annalisa Chiarenza and Andrea Visentin and Daniela Pietrasanta and Giacomo Loseto and Antonella Zucchetto and Riccardo Bomben and Jacopo Olivieri and Antonio Neri and Davide Rossi and Gianluca Gaidano and Livio Trentin and Robin Fo{\`a} and Antonio Cuneo and Chava Perry and Valter Gattei and Massimo Gentile and Yair Herishanu",

note = "Funding Information: The present study is supported in part by: Progetto Ricerca Finalizzata PE‐2016‐02362756, and RF‐2018‐12 365 790, Italian Ministry of Health, Rome, Italy; Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG‐21687; Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore/Veneto Orientale Group, Italy; Fundaci{\`o} La Marat{\`o} de TV3 (Spain); Linfo‐check ‐ Bando ricerca ‐ contributo art. 15, comma 2, lett (b) LR 17/2014; “5 × 1000 Intramural Program”, Centro di Riferimento Oncologico, Aviano, Italy.",

year = "2023",

month = feb,

doi = "10.1002/ajh.26779",

language = "الإنجليزيّة",

volume = "98",

pages = "E24--E27",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

Levi, S, Bronstein, Y, Goldschmidt, N, Morabito, F, Ziv-Baran, T, Del Poeta, G, Bairey, O, Del Principe, MI, Fineman, R, Mauro, FR, Gutwein, O, Reda, G, Ruchlemer, R, Sportoletti, P, Laurenti, L, Shvidel, L, Coscia, M, Tadmor, T, Varettoni, M, Aviv, A, Murru, R, Braester, A, Chiarenza, A, Visentin, A, Pietrasanta, D, Loseto, G, Zucchetto, A, Bomben, R, Olivieri, J, Neri, A, Rossi, D, Gaidano, G, Trentin, L, Foà, R, Cuneo, A, Perry, C, Gattei, V, Gentile, M & Herishanu, Y 2023, 'Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study', American Journal of Hematology, vol. 98, no. 2, pp. E24-E27. https://doi.org/10.1002/ajh.26779

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study. / Levi, Shai; Bronstein, Yotam; Goldschmidt, Neta et al.
In: American Journal of Hematology, Vol. 98, No. 2, 02.2023, p. E24-E27.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

T2 - A retrospective multicenter “Real-World” study

AU - Levi, Shai

AU - Bronstein, Yotam

AU - Goldschmidt, Neta

AU - Morabito, Fortunato

AU - Ziv-Baran, Tomer

AU - Del Poeta, Giovanni

AU - Bairey, Osnat

AU - Del Principe, Maria Ilaria

AU - Fineman, Riva

AU - Mauro, Francesca Romana

AU - Gutwein, Odit

AU - Reda, Gianluigi

AU - Ruchlemer, Rosa

AU - Sportoletti, Paolo

AU - Laurenti, Luca

AU - Shvidel, Lev

AU - Coscia, Marta

AU - Tadmor, Tamar

AU - Varettoni, Marzia

AU - Aviv, Ariel

AU - Murru, Roberta

AU - Braester, Andrei

AU - Chiarenza, Annalisa

AU - Visentin, Andrea

AU - Pietrasanta, Daniela

AU - Loseto, Giacomo

AU - Zucchetto, Antonella

AU - Bomben, Riccardo

AU - Olivieri, Jacopo

AU - Neri, Antonio

AU - Rossi, Davide

AU - Gaidano, Gianluca

AU - Trentin, Livio

AU - Foà, Robin

AU - Cuneo, Antonio

AU - Perry, Chava

AU - Gattei, Valter

AU - Gentile, Massimo

AU - Herishanu, Yair

N1 - Funding Information: The present study is supported in part by: Progetto Ricerca Finalizzata PE‐2016‐02362756, and RF‐2018‐12 365 790, Italian Ministry of Health, Rome, Italy; Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG‐21687; Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore/Veneto Orientale Group, Italy; Fundaciò La Maratò de TV3 (Spain); Linfo‐check ‐ Bando ricerca ‐ contributo art. 15, comma 2, lett (b) LR 17/2014; “5 × 1000 Intramural Program”, Centro di Riferimento Oncologico, Aviano, Italy.

PY - 2023/2

Y1 - 2023/2

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Cyclophosphamide/therapeutic use

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy

KW - Rituximab/therapeutic use

KW - Vidarabine/therapeutic use

UR - https://www.scopus.com/pages/publications/85145944390

U2 - 10.1002/ajh.26779

DO - 10.1002/ajh.26779

M3 - رسالة

C2 - 36349541

SN - 0361-8609

VL - 98

SP - E24-E27

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this